Establishment of highly invasive pancreatic cancer cell lines and the expression of IL-32.
cell culture
comprehensive genomic analysis
interleukin-32
invasion
pancreatic cancer cell
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
15
12
2019
accepted:
27
05
2020
entrez:
13
8
2020
pubmed:
13
8
2020
medline:
13
8
2020
Statut:
ppublish
Résumé
Compared to tumors of other organs, pancreatic cancer is highly aggressive; with one of its biological features being that, despite a prominent fibrotic stroma, there is remarkable infiltration of tumor cells. This characteristic is considered to be the main reason for the poor prognosis of patients with pancreatic cancer. Therefore, in order to elucidate the factors that contribute to this high invasiveness, a selective invasion method was used to establish four highly invasive subclones from six human pancreatic cancer cell lines. The results demonstrated that two cell lines did not exhibit enhanced invasiveness. Microarray analysis revealed that, in the highly invasive cell lines, several genes were expressed at high levels, compared with the original cell lines. These highly expressed genes were recognized only in highly invasive cells. Among them,
Identifiants
pubmed: 32782605
doi: 10.3892/ol.2020.11825
pii: OL-0-0-11825
pmc: PMC7400074
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2888-2896Informations de copyright
Copyright: © Takagi et al.
Références
J Biol Chem. 2009 Jun 26;284(26):17868-76
pubmed: 19386602
Biomedicines. 2017 Nov 18;5(4):
pubmed: 29156578
Nat Rev Dis Primers. 2016 Apr 21;2:16022
pubmed: 27158978
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Int J Oncol. 1998 Oct;13(4):669-76
pubmed: 9735394
Transl Oncol. 2019 Mar;12(3):475-484
pubmed: 30594036
Immunity. 2005 Jan;22(1):131-42
pubmed: 15664165
Front Med. 2018 Aug;12(4):387-411
pubmed: 30043220
Oncol Lett. 2012 Feb;3(2):490-496
pubmed: 22740938
Cancer Sci. 2003 Aug;94(8):699-706
pubmed: 12901795
Semin Immunol. 2018 Aug;38:24-32
pubmed: 29747940
Onco Targets Ther. 2016 Jul 11;9:4225-37
pubmed: 27471397
Cancer Lett. 2012 May 28;318(2):226-33
pubmed: 22198481
Oncol Lett. 2015 Jan;9(1):305-307
pubmed: 25435980
Nat Med. 2016 May;22(5):497-505
pubmed: 27089513
Clin Cancer Res. 2012 Aug 15;18(16):4257-65
pubmed: 22896692
Lancet. 2011 Aug 13;378(9791):607-20
pubmed: 21620466
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Science. 2008 Sep 26;321(5897):1801-6
pubmed: 18772397
World J Gastroenterol. 2016 Nov 28;22(44):9694-9705
pubmed: 27956793